

Caldeira, Sónia (sonia.caldeira@infarmed.pt); Correia, Ana (ana.correia@infarmed.pt); Furtado, Cláudia (claudia.furtado@infarmed.pt);

Oliveira, Margarida (margarida.oliveira@infarmed.pt); Silva, Patrícia (patricia.silva@infarmed.pt)

INFARMED - National Authority of Medicines and Health Products, I.P.

Population \*: 10,4M

GDP per capita\*: 20.217 €

NHS (tax funded system):

Health expenditure \*: 10,6% GDP

NHS pharma expenditure #:

- NHS Ambulatory care: 1 593,8 M€

- NHS Hospital care: 1 959,2 M€

\* [www.ine.pt](http://www.ine.pt) / [www.pordata.pt](http://www.pordata.pt) (2022)


# [www.infarmed.pt](http://www.infarmed.pt) (2023)

## Pharmaceutical pricing and reimbursement policies

HTA





Ministry of Health (MoH)



PRICING


OUT - PATIENT

IN-PATIENT: Applied only to Public hospitals




REIMBURSEMENT/FINANCING

Ministry of Health or INFARMED (currently power delegation on generics, biosimilars and reimbursement delist)



PAYMENT

Ministry of Health through ACSS (Central Administration of the Health System)



Legislation: Decree-Law n.º 97/2015, 1<sup>st</sup> June; Ordinance n.º 195-C/2015, 30<sup>th</sup> June; Ordinance n.º 195-A/2015, 30<sup>th</sup> June; Ordinance n.º 195-D/2015, 30<sup>th</sup> June; Decree-Law n.º 134/2005, 16<sup>th</sup> August; Ministerial Dispatch n.º 1547-B/2016; European Directives 2004/17/CE and 2004/18/CE; Ministerial Dispatch n.º 1083/2004